Crossmark

Neutralizing activity against Omicron subvariants BA.1, BA.2, and BA.4/5 following the third SARS-CoV-2 vaccination in cancer patients undergoing chemotherapy

Crossref DOI link: https://doi.org/10.1016/j.clinsp.2025.100757

Published Print: 2025-01

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Yun, Jina https://orcid.org/0000-0001-5897-8309
Kim, Bora https://orcid.org/0000-0002-6836-4682
Kim, Hyuk https://orcid.org/0009-0008-5214-7430
Lim, Sung Hee https://orcid.org/0000-0003-0845-9994
Choi, Seong Hyeok https://orcid.org/0000-0002-1280-7798
Kim, Ji Youn https://orcid.org/0000-0002-7605-801X
Kim, Hyun Jung https://orcid.org/0009-0002-3589-5847
Park, Seong Kyu https://orcid.org/0000-0002-3055-3621
Funding

Funding for this research was provided by:

Soonchunhyang University
License Information

Text and Data Mining valid from 2025-01-01

Text and Data Mining valid from 2025-01-01

Version of Record valid from 2025-08-08
More Information

This article is maintained by: Elsevier

Article Title: Neutralizing activity against Omicron subvariants BA.1, BA.2, and BA.4/5 following the third SARS-CoV-2 vaccination in cancer patients undergoing chemotherapy

Journal Title: Clinics

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.clinsp.2025.100757

Content Type: article

Copyright: © 2025 HCFMUSP. Published by Elsevier España, S.L.U.

Document is current

Any future updates will be listed below